United States, Sept. 11 -- Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci's generative AI Drug Creation Platform leverages OCI's AI infrastructure and AMD's latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.To advance Absci's mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large...